PODDMEDIUM SIGNALFINANCIAL10-K

PODD shows strong operational performance with 31% revenue growth and 53% operating income increase, but net income declined 41% despite robust business fundamentals.

The disconnect between strong operating performance and declining net income suggests significant one-time items or tax effects that warrant investigation. The substantial cash position increase to $907M and strong operating cash flow growth indicate solid financial health and funding capacity for continued expansion.

Comparing 2026-02-18 vs 2025-02-21View on EDGAR →
FINANCIAL ANALYSIS

PODD delivered impressive top-line growth with revenue increasing 31% to $2.7B and operating income surging 53% to $474M, demonstrating strong operational leverage. However, net income fell 41% to $247M despite the strong operating performance, indicating significant non-operating charges or tax impacts. The company's financial position strengthened considerably with cash rising 325% to $907M and operating cash flow growing 32%, while increased R&D spending (+37%) and capex (+53%) signal continued investment in growth initiatives.

FINANCIAL STATEMENT CHANGES
Net Interest Income
P&L
+1860%
$500K$9.8M

Net interest income grew 1860% — benefiting from rate environment or loan book expansion.

Cash & Equivalents
Balance Sheet
+324.5%
$213.7M$907.2M

Cash position surged 324.5% — strong cash generation or capital raise providing significant financial cushion.

Operating Income
P&L
+53.4%
$308.9M$473.8M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Capital Expenditure
Cash Flow
+53.4%
$124.9M$191.6M

Capital expenditure jumped 53.4% — major investment cycle underway; assess returns on deployment.

Net Income
P&L
-40.9%
$418.3M$247.1M

Net income declined 40.9% — review whether driven by operations, interest costs, or non-recurring items.

R&D Expense
P&L
+37.1%
$219.6M$301.1M

R&D investment increased 37.1% — signals commitment to future product development, though near-term margin impact.

Gross Profit
P&L
+34.2%
$1.4B$1.9B

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Operating Cash Flow
Cash Flow
+32.3%
$430.3M$569.3M

Operating cash flow surged 32.3% — exceptional cash generation, highest quality earnings signal.

Revenue
P&L
+30.7%
$2.1B$2.7B

Strong top-line growth of 30.7% — accelerating demand or successful expansion into new markets.

Current Liabilities
Balance Sheet
+28.7%
$528.4M$680.1M

Current liabilities rose 28.7% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-02-18
PRIOR — 2025-02-21
ADDED
Historically, type 2 diabetes has occurred in later adulthood, but its incidence is increasing among children and young adults, due primarily to increasing obesity.
and international insulin-requiring type 2 diabetes population and the U.S.
MDI therapy also requires a separate injection of a long-acting (basal) insulin, to control glucose levels between meals.
The small, lightweight, self-adhesive disposable tubeless Omnipod device ( Pod ), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back.
Omnipod products provide for virtually pain-free automated cannula (a small flexible tube) insertion through which insulin is delivered, eliminating the need for MDI or the use of pump and tubing.
+7 more — sign up free →
REMOVED
Historically, type 2 diabetes has occurred in later adulthood, but its incidence is increasing among the younger population, due primarily to increasing obesity.
and international insulin-intensive type 2 diabetes population and the U.S.
MDI therapy may also require a separate injection of a long-acting (basal) insulin, to control glucose levels between meals; typically, once or twice per day.
The small, lightweight, self-adhesive disposable tubeless Omnipod device ( Pod ), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube (called a cannula).
The embedded algorithm utilizes these glucose values to predict glucose levels into the future and automatically adjusts insulin dosing intended to improve time-in-range and reduce the occurrence of blood glucose highs and lows.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →